Alzheimer's disease (AD) is the most common form of dementia and is characterised by
progressive impairment in cognitive function and behaviour. The pathological features of AD …

Background The hypothesis that amyloid deposition is the leading cause of Alzheimer's
disease (AD) is supported by findings in transgenic animal models and forms the basis of …

Background Amyloid-β (Aβ) plaque formation is a hallmark of Alzheimer's disease (AD) and
precedes the onset of dementia. Aβ imaging should allow earlier diagnosis, but clinical …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Over the past two decades, the landscape of dementia research has changed drastically
due to advances in knowledge at the molecular, cellular, animal, and human levels …

Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease …

Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

Technological advances have led to greater use of both structural and functional brain
imaging to assist with the diagnosis of dementia for the increasing numbers of people with …

Alzheimer's disease (AD) is a complex neurodegenerative disorder of which the exact cause
is still not known. There has, however, been remarkable progress in the understanding of …

Background Results of previous studies have shown associations between PET imaging of
amyloid plaques and amyloid-β pathology measured at autopsy. However, these studies …